Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. [electronic resource]
Producer: 20120716Description: 4387-90 p. digitalISSN:- 1528-0020
- Amyloid -- metabolism
- Amyloidosis -- drug therapy
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Boronic Acids -- administration & dosage
- Bortezomib
- Clonal Evolution -- drug effects
- Cohort Studies
- Cyclophosphamide -- administration & dosage
- Dexamethasone -- administration & dosage
- Disease-Free Survival
- Female
- Humans
- Male
- Middle Aged
- Pyrazines -- administration & dosage
- Recurrence
- Retrospective Studies
- Treatment Outcome
No physical items for this record
Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.